Alder Drug Fights Cancer Fatigue

Xconomy Seattle — 

Alder Biopharmaceuticals, the Bothell, WA-based developer of targeted antibody drugs, said today that its lead drug candidate was found to be safe and reduce severe fatigue of patients in an early-stage study of patients with advanced cancer. The trial enrolled nine patients who got ALD518, an antibody that’s designed to block an inflammatory protein called IL-6. The preliminary results were presented at the American Society of Clinical Oncology meeting in Orlando, FL. The drug is now being tested in a larger study of 124 cancer patients, which is expected to complete enrollment by the end of 2009.